Brand Intelligence Graphcompany
Company Overview
About PostEra
PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.
Business Model & Competitive Advantage
PostEra's Proton AI platform addresses the medicinal chemistry design bottleneck in drug discovery: identifying a promising drug target (a protein or biological mechanism involved in disease) is the starting point, but optimizing a small molecule drug candidate from initial hit to clinical candidate requires designing hundreds of molecular variants that systematically improve potency, selectivity, metabolic stability, and drug-likeness while maintaining synthesizability — a chemistry design-make-test cycle that takes medicinal chemistry teams 2-4 years of iterative laboratory work. PostEra's ML models (trained on synthesis pathway data and structure-activity relationship datasets) generate molecular designs that are both biologically optimized for the target and practically synthesizable by chemistry teams — reducing the design-to-synthesis cycle by predicting which molecular modifications will improve properties without creating unsynthesizable structures. The ADC design capability (predicting optimal drug-linker-antibody conjugation sites and payload chemistry for homogeneous ADC drug-to-antibody ratios) addresses the hottest growth area in oncology drug development.
Competitive Landscape 2025–2026
In 2025, PostEra competes in the AI drug discovery, computational chemistry, and medicinal chemistry AI market with Schrödinger (NASDAQ: SDGR, physics-based drug design software, $1.5B raised), Recursion Pharmaceuticals (NASDAQ: RXRX, AI drug discovery, $800M raised), and Insilico Medicine (AI drug discovery, $400M raised) for pharmaceutical company AI-accelerated medicinal chemistry and lead optimization adoption. The $610M Pfizer collaboration expansion (January 2025) represents one of the largest AI drug discovery partnership expansions in 2025 and validates PostEra's commercial model of technology licensing plus milestone economics for pharma partnerships. The 40% faster preclinical milestone achievement demonstrates the AI acceleration value proposition at the most risk-intensive stage of pharmaceutical development. The 2025 strategy focuses on expanding the Pfizer and Amgen program scope, signing additional top-10 pharma collaborations for new therapeutic areas, and building the ADC design platform for the oncology ADC market.
Recent Activity
View all →Key Differentiators
Market Leader
PostEra is recognized as a market leader in the Healthcare sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Compare PostEra with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from PostEra? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim PostEra Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention PostEra vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →